All News

Maroney discussed the pharmacist’s role in patient education, safe medication management, and incorporating broader treatment strategies into individualized mental health care plans.

FDA Recall targets True Metrix blood glucose monitoring systems after E-5 errors risk mistreating diabetes; updated guidance helps patients, pharmacists prevent harm.

A single dose of psilocybin produced rapid and clinically meaningful reductions in depressive symptoms in patients with major depressive disorder.

FDA approves benralizumab for hypereosinophilic syndrome, driven by NATRON phase 3 clinical trial data showing fewer flares and improved fatigue.

The ruling comes after weeks of uncertainty for patients, health care providers, and pharmacists about how and whether they could access and distribute the drug.

Laughing gas misuse is surging as nitrous oxide drug abuse spreads online

Phase 3 SCORPIO-PEP trial shows ensitrelvir cuts symptomatic COVID-19 after household exposure, boosting postexposure prophylaxis options for high-risk patients.

This week’s episode covers Marty Makary’s resignation as FDA commissioner, evolving hepatitis B vaccination efforts, and new FDA approvals in asthma and precision oncology.

Neurology pharmacists drive safer medication changes, boost access and financial assistance, and deliver major cost savings through high-impact outpatient pharmacist intervention.

Securing executive buy-in, building multidisciplinary coalitions, and targeting inappropriate antiplatelet use are among the most critical steps in implementing antithrombotic stewardship programs.

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

A novel urine-based test outperformed mpMRI in detecting prostate cancer progression and may help reduce unnecessary biopsies.

Patients with CKD and GERD who initiated P-CABs had a 37% lower risk of needing renal replacement therapy.

Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.

Data from the STEP UP trial support semaglutide 7.2 mg as a well-tolerated option for patients who need greater weight reduction.

Pharmacists can guide the appropriate use of nonprescription therapies, reinforce recommended prevention strategies, and encourage patients to seek medical evaluation when warranted.

FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

The commissioner's sudden departure leaves the agency navigating a crowded agenda of unresolved policy questions—many with direct implications for pharmacists and their patients.

FDA approves sonrotoclax for patients who have received at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

Newborn vitamin K shot refusals rise, boosting bleeding risk; learn neonatal safety facts and how the vitamin K shot prevents deadly VKDB.

As medetomidine rapidly displaces xylazine as a fentanyl adulterant, pharmacists must recognize its distinct toxidrome, understand why naloxone alone is insufficient, and support updated harm reduction strategies in an increasingly complex overdose landscape.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the safety profile of Levorphanol compared with methadone, including potential reductions in risks such as accumulation, QT prolongation, and drug interactions, as well as its implications for clinical workflows and the pharmacist’s role in supporting safe opioid rotation, monitoring, and patient counseling.

Darren Triller, PharmD, makes the case for system-level solutions over individual clinical effort, introducing the ADAPT framework

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and examines how levorphanol compares to methadone in pharmacology and clinical efficacy, as well as the key evidence supporting its use and the practical barriers clinicians face when transitioning between the two agents in complex pain management.

A new JAMA study links GLP-1s like Wegovy, Ozempic, Zepbound, and Mounjaro to better breast cancer survival, lower recurrence, and weight loss benefits.

Recent randomized trials and CDC guidance support doxycycline postexposure prophylaxis as a targeted strategy to reduce bacterial STIs in high-risk populations.

The study authors also emphasized that close monitoring during gabapentinoid treatment is necessary, and concomitant use with opioids or benzodiazepines should be avoided.